Cytochrome P4502C9 induces cycloxygenase-2 expression in endothelial cells

被引：0
|
作者：
Michaelis, UR [1 ]
Fisslthaler, B [1 ]
Fleming, I [1 ]
Busse, R [1 ]
机构：
[1] Klinikum JWG Univ, Frankfurt, Germany
来源：
EUROPEAN HEART JOURNAL | 2003年 / 24卷
关键词：
D O I：
10.1016/S0195-668X(03)93694-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [31] Substance P-induced cycloxygenase-2 expression in polymorphonuclear cells
    M. Gallicchio
    E. Benetti
    A. C. Rosa
    R. Fantozzi
    Inflammation Research, 2008, 57 : 17 - 18
  • [32] Early acenocoumarol overanticoagulation among cytochrome P4502C9 poor metabolisers
    Verstuyft, C
    Morin, S
    Robert, A
    Loriot, MA
    Beaune, P
    Jaillon, P
    Becquemont, L
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R113 - R113
  • [33] Early acenocoumarol overanticoagulation among cytochrome P4502C9 poor metabolizers
    Verstuyft, C
    Morin, S
    Robert, A
    Loriot, MA
    Beaune, P
    Jaillon, P
    Becquemont, L
    PHARMACOGENETICS, 2001, 11 (08): : 735 - 737
  • [34] Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
    Miners, JO
    Birkett, DJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (06) : 525 - 538
  • [35] Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population
    Scordo, MG
    Aklillu, E
    Yasar, U
    Dahl, ML
    Spina, E
    Ingelman-Sundberg, M
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) : 447 - 450
  • [36] Cytochrome P4502C9 activity in end-stage renal disease
    Dreisbach, AW
    Japa, S
    Gebrekal, AB
    Mowry, SE
    Lertora, JJL
    Kamath, BL
    Rettie, AE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (05) : 475 - 477
  • [37] Tamoxifen inhibits cytochrome P4502C9 activity in breast cancer patients
    Boruban, M. C.
    Yasar, U.
    Babaoglu, M. O.
    Sencan, O.
    Bozkurt, A.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (04) : 421 - 424
  • [38] The risk of myocardial infarction in patients with reduced activity of cytochrome P4502C9
    Visser, Loes E.
    van Schaik, Ron H. N.
    Danser, Alexander H. Jan
    Hofman, Albert
    Witteman, Jacqueline C. M.
    van Duijn, Cornelia M.
    Uitterlinden, Andre G.
    Pols, Huibert A. P.
    Stricker, Bruno H. Ch.
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (07): : 473 - 479
  • [39] Frequency of cytochrome P4502C9 allelic variants in the Chinese and French populations
    Yang, JQ
    Morin, S
    Verstuyft, C
    Fan, LA
    Zhang, Y
    Di Xu, C
    Barbu, V
    Jaillon, P
    Becquemont, L
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (03) : 373 - 376
  • [40] Comparison of cytochrome P4502C9 genotyping methods and implications for the clinical laboratory
    Aquilante, CL
    Lobmeyer, MT
    Langaee, TY
    Johnson, JA
    PHARMACOTHERAPY, 2004, 24 (06): : 720 - 726
12345